2Hopkins R J, Girardi L S, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric uleerrecurrence: are-view. Gastroenterology, 1996, 110( 4 :244-1252.
1Kato M, Ono S, Nakagawa M, el al. Posilion of NSAIDs in causal faclors of peplic ulcer. Nippon Rinsho, 2007, 65: 1760-1767.
2Konturek SJ, Konturek PC, Konturek JW, et al. Helicobacter pylori and its involvement in gastritis and peptic ulcer formation. J Physiol Pharmacol,2006,57 (Suppl 3) : 29-50.
3Atherton JC. The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol, 2006,1: 63-96.
4Hamajima N. Persistent Helicobacter pylori infection and genetic polymorphisms of the host. Nagoya J Med Sci, 2003, 66:103-117.
5Garcia-Gonzalez MA, Strunk M, Piazuelo E, et al. TGFβ1 gene polymorphisms: their relevance in the susceptibility to Helicobacter pylori-related diseases. Genes Immun, 2006,7 640-646.
6Wilschanski M, Schlesinger Y, Faber J,et al. Combination of Helicobacter pylori strain and tumor necrosis factor-alpha polymorphism of the host increases the risk of peptic ulcer disease in children. J Pediatr Gastroenterol Nutr, 2007,45: 199-203.
7Iwakiri R. NSAIDs and its gastrointestinal side effects: relation of NSAIDs variety and influence of concomitant medicine. Nippon Rinsho,2007,65 : 1776 1780.
8Yajima H, Yamao J, Fukui H, el al. Up-to-date information on gaslric mucosal lesions from long-term NSAID therapy in orlhopedic outpatients: a study using logistic regression analysis. J OrthopSci,2007,12: 341-346.
9Konlurek PC, Konturek SJ, Czegnikiewicz M, et al. Interaclion of Helicobacter pylori (Hp) and nonsteroidal antiinflammalory drugs (NSAID) on gaslric mucosa and risk of ulcerations. Med Sci Monit,2002,8: RA197-RA209.
10de Leesl HT, Steen KS, Lems WF, el al. Eradicalion of Helicobacler pylori does not reduce lhe incidence of gaslroduodenal ulcers in palients on long-lerm NSAID trealment: double-blind, randomized, placebo-controlled lrial. Helicobacter,2007,12:477-485.
